- Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Henry G. Kaplan et al, 2022, Breast Cancer Research and Treatment CrossRef - Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects
Rahman Ladak et al, 2024, Cureus CrossRef - A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting
Praneet Singh Bedi et al, 2023, Journal of Cancer Research Updates CrossRef